Paul Jaeger

Comparison of time to therapy initiation, therapeutic strategies and survival in patients with MDS IB1, IB2 and AML-MR using data of the duesseldorf registries

Abstract In 2022, the ICC redefined AML by lowering marrow blast count to 10% herewith integrating former MDS IB2 into AML. To evaluate the clinical implications of this reclassification, we analyzed data of our Duesseldorf registries regarding different aspects in patients with...